BGOG-EN20/XPORT-EC-042

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Open
Prior lines
1, 2
Histology
Endometrioid, Serous Carcinocarcoma Other (bv. mixed/rare)
Phase
III

Treatment

This study consists of two different treatment options: 

  • Selinexor
  • Placebo

Selinexor and placebo are administered once per week as a tablet.

You will be randomly allocated to one of either treatment groups. 
This trial is a maintenance treatment and will therefore only be administered after completing your chemotherapy in case this was sufficiently successful.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.